# US 2019/0314319 A1 · Combination therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314319 A1
- Document ID: US20190314319A1
- Status: Published application
- Kind: A1
- Application number: 16/078,325
- Filed: 2017-02-23
- Published: 2019-10-17
- Earliest claimed: 2016-02-23
- Assignees: Imbria Pharmaceuticals, Inc.
- Applicants: Imbria Pharmaceuticals, Inc.
- Inventors: Andrew D. Levin
- Web page: https://patentgrep.com/patent/US20190314319A1

## CPC

- A61K 31/225: Polycarboxylic acids
- C07C 69/40: Succinic acid esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.

## Claims

### Claim 1

A compound having the structure of formula I:
or a salt thereof, wherein:
each of R1, R2 and R3 is independently —H, —OH, R, or R—C(O)O—, or may be independently and optionally taken together with a hydrogen atom on the carbon atom to which it is attached to form an oxo group;
each R is independently linear or branched C1-C100 aliphatic wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—, and any two or more R groups may be linked by one or more linear or branched, bivalent or polyvalent, C1-C100 hydrocarbon group wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—;
at least one of R1, R2 and R3 is R—C(O)O—; and
wherein when each ester group of the compound of formula I is hydrolyzed into its corresponding —OH and —COOH groups, each hydrolysis product is independently a compound selected from a TCA cycle acid or a salt thereof, a C2-C20 diol or polyol, and R′—C(O)OH or a salt thereof;
R′ is C1-C20 aliphatic wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—; and
at least one hydrolysis product is a TCA cycle acid or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
each of R1, R2 and R3 is independently —H, —OH, R, or R—C(O)O—, or may be independently and optionally taken together with a hydrogen atom on the carbon atom to which it is attached to form an oxo group;
each R is independently linear or branched C1-C100 aliphatic wherein one or more —CH2— units are independently replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—, and any two or more R groups may be linked by one or more linear or branched, bivalent or polyvalent, C1-C100 hydrocarbon group wherein one or more —CH2— units are independently replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—;
at least one of R1, R2 and R3 is R′—C(O)O—; and
wherein when each ester group of the compound of formula I is hydrolyzed into its corresponding —OH and —COOH groups, each hydrolysis product is independently a compound selected from a TCA cycle acid or a salt thereof, a C2-C20 diol or polyol, and R′—C(O)OH or a salt thereof;
R′ is C1-C20 aliphatic wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—; and
at least one hydrolysis product is a TCA cycle acid or a salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein a C2-C20 diol or polyol is glycerol.

### Claim 4 (depends on 3)

The compound of claim 3, wherein the compound comprises at least 3 R′—C(O)O— groups.

### Claim 5 (depends on 3)

The compound of claim 3, wherein the compound contains four R′—C(O)O— groups.

### Claim 6 (depends on 4)

The compound of claim 4, wherein each of R2 and R3 is independently R′—C(O)O—.

### Claim 7 (depends on 4)

The compound of claim 4, wherein R1 is branched C15-C100, aliphatic wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, or —C(O)O—.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R1 is —OC(O)—CH2—CH2—C(O)O—R, wherein R contains two R′—C(O)O— groups.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound has the structure of formula I-a:
or a salt thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R′ is C1-C11 linear alkyl.

### Claim 11 (depends on 9)

The compound of claim 9, wherein R′ is C3-C7 linear alkyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is selected from compounds I-1, I-8 to I-15, I-17 to I-19, I-21, and I-23 to I-31, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 10)

The compound of claim 10, wherein the compound has a purity of no less than about 90%.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method, comprising administering to a subject suffering from or susceptible to a disease, disorder or condition a pharmaceutically effective amount of a compound of any one of claims 1-16.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease, disorder or condition is an energetic disorder, refractory epilepsy, propionic acidemia (PA), methylmalonic acidemia (MMA), a long chain fatty acid oxidation disorder, succinyl-CoA lyase deficiency, pyruvate carboxylase deficiency, mitochondrial respiratory chain deficiencies, glutaric acidemia type 1, glutaric acidemia type 2, neurologic disease, disorder or condition, Huntington's disease, disorder or condition, Parkinson's disease, disorder or condition, Alzheimer's disease, disorder or condition, cancer, pain or fatigue disease, muscular dystrophy, Duchenne's muscular dystrophy, Becker's muscular dystrophy, mitochondrial myopathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS), myoclonic epilepsy and ragged-red fibers (MERRF), a mitochondrial associated disease, or a disease, disorder or condition related to POLG mutation.

### Claim 19 (depends on 17)

The method of claim 17, wherein the compound is administered by direct drinking of the compound.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is administered at at least about 1 g/kg per day.
